GlobalData on MSN
REGENXBIO completes wet AMD gene therapy trial enrolment
The active-controlled, multicentre, randomised studies are aimed at supporting regulatory submissions of sura-vec globally.
The ZUMA-24 study showed outpatient axicabtagene ciloleucel (axi-cel) for DLBCL reduced hospitalization and improved safety profiles. CAR T-cell therapy for DLBCL shows promise in outpatient settings, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback